Empagliflozin for Heart Failure in Patients Without Diabetes | 合法藥品大搜索

Read More

由 M Packer 著作 · 2020 · 被引用 631 次 — In our trial, the combined risk of cardiovascular death or hospitalization for heart failure was 25% lower among the patients who received ... Read More

2021年1月28日 — (Oct. 8 issue)1 found that empagliflozin was associated with a lower risk than placebo of a composite outcome of cardiovascular death or ... Read More

由 M Packer 著作 · 2021 · 被引用 4 次 — When compared with placebo, empagliflozin reduced the composite risk of cardiovascular death or hospitalization for heart failure, decreased ... Read More

2021年4月14日 — The EMPEROR-Reduced trial showed that empagliflozin is superior to placebo in improving HF outcomes among patients with symptomatic ... Read More

2020年5月15日 — Among patients with heart failure and diabetes mellitus, empagliflozin therapy resulted in increased natriuresis as monotherapy and ... Read More

2021年3月11日 — We know from large clinical trials that sodium–glucose cotransporter-2 (SGLT-2) inhibitors improve outcomes for patients with heart failure (HF), ... Read More

2021年1月11日 — In addition to the primary end point, empagliflozin may also reduce the rate at which kidney function worsens in patients with HFrEF. Also known ... Read More

由 M Packer 著作 · 2021 · 被引用 4 次 — When compared with placebo, empagliflozin reduced the composite risk of cardiovascular death or hospitalization for heart failure, decreased ... Read More